NCT05178862Phase 3Terminated

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Study sponsor: Scynexis, Inc. · SCYX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-11-07Actual
Enrollment · participants68Actual
Source updated2026-08-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: All-cause mortality (US FDA Only) Measure: Global Response at End of Treatment (EU European Medicines Agency [EMA] Only). After: Measure: All-cause Mortality Measure: Global Response at End of Treatment (EU European Medicines Agency [EMA] Only).

Check registry source

· 3 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 31 Dec 2026. After: 7 Nov 2025.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview